On June 1st, 2019, the series of national training sessions on WHO hepatitis C guideline under China Hepatitis C Elimination Alliance Public Welfare Project first started in Chengdu, jointly hosted by China Liver Health, Sichuan Infectious Disease Diagnosis and Treatment Quality Control Center and Liver Disease Branch/Infectious Disease Branch of Sichuan Medical Association, and co-organized by West China Hospital of Sichuan University and Chengdu Public Health Clinical Medical Center. More than 230 healthcare workers from over 60 hospitals in Sichuan and other provinces attended the training session. More than 600 citizens received voluntary clinical service and hepatitis C antibody test for free at the scene.  He Qinghua, deputy director-general of the Disease Prevention and Control Bureau under National Health Commisssion, attended the training session and expressed gratitude to liver disease experts for their efforts in eliminating hepatitis. Director-general He pointed out that eliminating hepatitis C was one of the major tasks in implementing Healthy China 2030 initiative. By actively integrating social resources to jointly promote hepatitis C screening, detection, prevention and treatment, China Hepatitis C Elimination Alliance Public Welfare Project will be an effective attempt for infectious disease prevention and control.  He Qinghua, deputy director-general of the Disease Prevention and Control Bureau under National Health Commisssion, gave a speech.  Academician Zhuang Hui, honorary chairman of China Liver Health, interpreted the epidemic status and disease burden of hepatitis in mainland China.  Prof. Wei Lai, chairman of China Liver Health, chaired the WHO hepatitis C guideline training session. Prof. Wei Lai pointed out that there were about 10 million people infected with hepatitis C in China. According to the Global Health Sector Strategy on Viral Hepatitis (GHSS) adopted by the World Health Assembly, China should achieve the goal of 90% of HCV infections being diagnosed and 80% of confirmed cases being treated by 2030. In terms of this goal, health care workers in China still have a long way to go.  Director Liu Zhongfu from China CDC introduced the current epidemic status and prevention and control progress of hepatitis in China.  Dr. Chen Zhongdan from WHO representative office in China introduced the global strategy for viral hepatitis prevention and control.  Liu Yong, dean of Chengdu Public Health Clinical Medical Center, gave a speech on behalf of the organizers of the training session.  Prof. Tang Hong from West China Hospital of Sichuan University interpreted hepatitis C treatment strategy from the perspective of WHO guideline. Prof. Tang Hong pointed out that the new WHO hepatitis C guideline reflected the latest progress of hepatitis C treatment globally, introduced effective measures and experience of several countries in combating hepatitis C, recommended pan-genotypic drugs for hepatitis C, provided a convenient treatment plan for primary care physicians and common patients, and was worth learning for doctors in China.  Experts in the field of hepatology gave lectures. Prof. Tang Hong from West China Hospital of Sichuan University, vice dean Zeng Yilan from Chengdu Public Health Clinical Medical Center, Prof. Chen Guofeng from the Fifth Medical Center of PLA General Hospital, Prof. Huang Yuan from Beijing Tsinghua Changgung Hospital, Prof. Bai Lang from Infectious Disease Center under West China Hospital of Sichuan University, Prof. Zhu Xia and other famous experts gave lectures to the first-line doctors from the department of infectious disease, hepatology, gastroenterology and laboratory medicine, interpreting WHO hepatitis C guideline and discussing in depth the epidemic status of hepatitis C, antiviral treatment of special hepatitis C patients and how to easily and effectively clear hepatitis C virus.  Experts and healthcare workers in the field attend the training session. This activity was one of the series of activities of the China Hepatitis C Elimination Alliance Public Welfare Project. With academician Zhuang Hui, a foremost authority on hepatology, serving as the general counsel, the project aims to implement the National Viral Hepatitis Prevention and Control Plan (2017-2020), promote the integration of hepatitis C screening and management standards in China with international standards, improve the cure rate of hepatitis C and strengthen the management of adverse reactions. reactions.  Li Mingyang, director of China Liver Health, introduced the progress of China Hepatitis C Elimination Alliance Public Welfare Project. After the training session, a number of well-known liver disease experts, including Wei Lai, Tang Hong, Zeng Yilan and Bai Lang, went to the outpatient clinic of West China Hospital of Sichuan University, provided voluntary clinical service for hepatitis C and offered consulting service about hepatitis C prevention, diagnosis and treatment, follow-up, family care, etc. More than 600 people participated in the consultation and some received free tests for hepatitis C antibody and hepatitis B surface antigen.  Chengdu Human Resource and Social Security Bureau launched the reimbursement policy for hepatitis C under medical insurance in November 2018. According to the policy, the expenditure of hepatitis C drugs covered by medical insurance can be reimbursed at 60-80%. It only takes a few thousand yuan for an individual to completely cure hepatitis C and regain health. This policy will bring benefits to people and provide strong support for eliminating hepatitis C and promoting detection and treatment in Chengdu. Under the gauidance of health and disease control departments of Chengdu and relying on medical insurance policy on hepatitis C, China Hepatitis C Elimination Alliance Public Welfare Project will carry out in-depth cooperation with West China Hospital, Chengdu Public Health Clinical Medical Center and other medical institutions, provide supports for primary health care institutions to carry out health education for hepatitis C prevention and control in communities, provide help in the detection and diagnosis of high-risk groups so as to contribute to hepatitis C elimination in Chengdu. |
关注官方微信 
